Form 4: Bluebird Bio Executive Granted Stock Options
SEC Form 4 Filing
Joseph Vittiglio, Chief Business & Legal Officer of bluebird bio, Inc., was granted stock options to purchase 199,000 shares of common stock.
Summary
- Joseph Vittiglio, the Chief Business & Legal Officer of bluebird bio, Inc., was granted stock options on March 1, 2024.
- The stock options grant him the right to buy 199,000 shares of common stock at an exercise price of $1.56 per share.
- The options vest over a four-year period, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in equal monthly installments over the subsequent 36 months.
- Vittiglio also has a Power of Attorney agreement in place, allowing Sydney Gaylin and Christopher Krawtschuk to act on his behalf for SEC filings related to bluebird bio.
Sentiment
Score: 6
Explanation: The document itself is neutral, simply reporting a stock option grant. It's a standard practice, so neither particularly positive nor negative.
Positives
- The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing him to improve the company's performance.
Future Outlook
The document does not contain specific forward-looking statements about the company's future performance.
Industry Context
Stock option grants are a common practice in the biotechnology industry to attract and retain key executives and align their interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Comparable companies like CRISPR Therapeutics, Beam Therapeutics, and Editas Medicine also utilize stock options as part of their executive compensation strategy.
- The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the executive to drive company growth.
- Employees may see this as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| February 6, 2024 | Date of execution for the Limited Power of Attorney. |
| March 1, 2024 | Date of the stock option grant and start of the vesting period. |
| March 5, 2024 | Date of the Form 4 filing. |
| March 1, 2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.